Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax

Pfizer

These companies should benefit from vaccines, tests and beyond.

3 Top Coronavirus Stocks to Buy in  June

Bio-Rad Laboratories

PerkinElmer

Independent analysis shows some of the post-exposure tests work fairly well.

FDA Evaluates 5 More COVID-19 Antibody Tests

Abbott (ABT) also mentions certain guidelines related to product return, reporting, and customer assistance.

Abbott Stock Down on Urgent Field Safety Notice for TactiCath

A Goldman Sachs analyst just downgraded the medical device and healthcare company's stock.

Should You Sell Abbott Laboratories Stock?

Roche Holding AG

They're both leaders in COVID-19 diagnostics testing and a whole lot more. But one stock appears to be the better pick right now.

Better Coronavirus Stock: Abbott Labs or Roche?

Gilead Sciences

These big healthcare companies have strong COVID-19 programs plus a lot more.

3 Large-Cap Coronavirus Stocks Still Worth Buying

Questions surrounding the accuracy of its COVID-19 tests could cause problems for the company.

Is Abbott Labs Stock in Trouble?

ABBOTT PARK, Ill., May 21, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) announced today an interim analysis of an ongoing multi-site clinical study in urgent care clinics that indicates its ID NOW COVID-19 rapid test is showing strong agreement to lab-based molecular polymerase chain reaction...

Abbott Releases Interim Clinical Study Data on ID NOW COVID-19 Rapid Test Showing Strong Agreement to Lab-Based Molecular PCR Tests

The fastest COVID-19 test on the market just encountered some turbulence. But does this create a buying opportunity for long-term investors?

Is Abbott Labs Stock a Buy After Its COVID-19 Test Controversy?

Abbott (ABT) reported earnings 30 days ago. What's next for the stock?

Why Is Abbott (ABT) Down 6.4% Since Last Earnings Report?

President Donald Trump on Friday said he's not concerned about Abbott Laboratories' ABT, -2.18% rapid test for COVID-19, calling it "a great test.

Trump says he isn't concerned about Abbott's coronavirus test as FDA probes accuracy

Adverse event reports suggest the Abbott ID NOW test has been delivering a troubling number of false negative results.

FDA Warns Public About Inaccuracy Issues With Abbott's Coronavirus Test

The White House still has "confidence in the test," Health and Human Services Secretary Alex Azar says.

Abbott's inaccurate coronavirus test results may be due to 'user error,' US health secretary Azar says

Medical company Abbott has now launched five coronavirus tests. It's expected to take a sizable share of the market.

Is Abbott Stock A Buy As Coronavirus Test Accuracy Called Into Question?

The Food and Drug Administration (FDA) on Thursday warned that rapid novel coronavirus (COVID-19) testing kits developed by Abbott Laboratories (NYSE: ABT) are frequently returning false negatives, according to preliminary data.

FDA Warns Abbott's Coronavirus Rapid Test Kits Used By White House Possibly Shows False Negative

The alert comes after an NYU study showed the company’s tests missed diagnosing up to half of known positive cases.

FDA Warns Abbott Coronavirus Tests Could Be Inaccurate

The U.S. Food and Drug Administration said on Thursday that Abbott Laboratories’  speedy coronavirus test, which can deliver results within minutes and is used at the White House, could potentially be inaccurate but can still be used to test patients.

U.S. regulator is reviewing Abbott's fast COVID test after studies raise accuracy concerns

The U.S. Food and Drug Administration issued an alert on Thursday saying there is early data that suggests Abbott Labs' rapid coronavirus diagnostic test for Covid-19 may be delivering inaccurate results.

FDA: Data suggests Abbott's rapid coronavirus diagnostic test is delivering inaccurate results

ABBOTT PARK, Ill., May 14, 2020 /PRNewswire/ -- (NYSE: ABT) -- Abbott's ID NOW™ is the fastest molecular point-of-care rapid test available today and has been delivering reliable results when and where they're needed. The availability and ease-of-access of ID NOW, which delivers results...

Abbott Provides Update on ID NOW™

Abbott Laboratories refuted claims Thursday that its coronavirus test is about half as accurate as a rival diagnostic. But ABT stock continued to tumble for the third straight day.

Abbott Strikes Back Against Claims Its Coronavirus Test Is Inaccurate

The urgency to ramp up coronavirus testing in the U.S. "has eased the usual scrutiny" applied by the Food and Drug Administration before the release of a new test, according to the authors of the study.

Abbott's rapid coronavirus test misses positive cases, raising questions, NYU study finds

The company plans to ship 90 million of the laboratory-run blood tests for SARS-CoV-2 antibodies by the end of June.

Coronavirus Antibody Test From Abbott Receives Emergency Use Authorization

Shares of Abbott Laboratories ABT, +0.47% were up 0.1% in trading on Monday after the company announced that it received its second authorization from the Food and Drug Administration to market a COVID-19 antibody test.

Abbott gets second EUA for COVID-19 antibody test

Abbott plans to ship nearly 30 million tests this month and will have the capacity to ship 60 million tests in June.

FDA grants emergency use authorization to Abbott Labs' coronavirus antibody test

Researchers found the test correctly returned negative results 99.9% of the time and positive results 100% of the time.

News for Abbott Labs Stock (ABT)